Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed. Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hypertension and only as adjunct therapy in the treatment of heart failure. Hydralazine is no longer a first line therapy for thes...
Hydralazine is indicated alone or adjunct to standard therapy to treat essential hypertension. A combination product with isosorbide dinitrate is indicated as an adjunct therapy in the treatment of heart failure.
Creighton Community Health Center, Omaha, Nebraska, United States
University of Chicago, Chicago, Illinois, United States
University of Edinburgh - Western General Hospital, Edinburgh, United Kingdom
Vanderbilt University, Nashville, Tennessee, United States
Minneapolis VA Medical Center, Minneapolis, Minnesota, United States
Saint Vincents Hospital and Medical Center, New York, New York, United States
Boston Medical Center, Boston, Massachusetts, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.